Literature DB >> 18220732

Microtubule-stabilizing natural products as promising cancer therapeutics.

Brian M Gallagher1.   

Abstract

Paclitaxel and related taxanes exhibit their anticancer activity by promoting tubulin polymerization and stabilizing microtubules, which results in mitotic G2/M arrest and apoptosis. The clinical success of paclitaxel in treating a wide array of tumor types has led to numerous efforts to identify novel natural products with paclitaxel-like mechanisms of action, but which may overcome some of the liabilities of the taxanes. Although the list of natural products that share the paclitaxel-like mechanism is relatively small, it continues to expand and currently includes a number of structurally distinct classes. Despite the mechanistic similarities between these classes, differences exist which may translate into their differential efficacy in the clinic. The past several years have seen a considerable amount of pre-clinical and clinical progress in developing these novel microtubule-stabilizing natural products as cancer therapeutics. This review focuses primarily on recent advances published since 2002.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220732     DOI: 10.2174/092986707782794014

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Total synthesis of laulimalide: synthesis of the northern and southern fragments.

Authors:  Barry M Trost; W Michael Seganish; Cheol K Chung; Dominique Amans
Journal:  Chemistry       Date:  2012-02-03       Impact factor: 5.236

Review 2.  Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Authors:  Melissa M Gajewski; Laleh Alisaraie; Jack A Tuszynski
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

3.  Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function.

Authors:  Han-Zhang Xu; Ying Huang; Ying-Li Wu; Yong Zhao; Wei-Lie Xiao; Qi-Shan Lin; Han-Dong Sun; Wei Dai; Guo-Qiang Chen
Journal:  Cell Cycle       Date:  2010-07-10       Impact factor: 4.534

4.  Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

Authors:  G Salzano; R Riehle; G Navarro; F Perche; G De Rosa; V P Torchilin
Journal:  Cancer Lett       Date:  2013-10-04       Impact factor: 8.679

5.  Synthesis and bioactivity of a side chain bridged paclitaxel: A test of the T-Taxol conformation.

Authors:  Mathis Hodge; Qiao-Hong Chen; Susan Bane; Shubhada Sharma; Maura Loew; Abhijit Banerjee; Ana A Alcaraz; James P Snyder; David G I Kingston
Journal:  Bioorg Med Chem Lett       Date:  2009-03-21       Impact factor: 2.823

Review 6.  Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides.

Authors:  Chad D Hopkins; Peter Wipf
Journal:  Nat Prod Rep       Date:  2009-03-11       Impact factor: 13.423

Review 7.  Stimulating neuroregeneration as a therapeutic drug approach for traumatic brain injury.

Authors:  Bernhard K Mueller; Reinhold Mueller; Hans Schoemaker
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

8.  Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Authors:  Arati Sharma; Arun K Sharma; Subbarao V Madhunapantula; Dhimant Desai; Sung Jin Huh; Paul Mosca; Shantu Amin; Gavin P Robertson
Journal:  Clin Cancer Res       Date:  2009-02-10       Impact factor: 12.531

9.  Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel.

Authors:  Anthony Stanislaus; Athirah Bakhtiar; Diyana Salleh; Snigdha Tiash; Tahereh Fatemian; Sharif Hossain; Toshihiro Akaike; Ezharul Hoque Chowdhury
Journal:  Cancer Cell Int       Date:  2012-06-18       Impact factor: 5.722

10.  Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.

Authors:  Zong-Keng Kuo; Mei-Wei Lin; I-Huang Lu; Hsin-Jan Yao; Hsin-Chieh Wu; Chun-Chung Wang; Shyh-Horng Lin; Si-Yuan Wu; Tien-Soung Tong; Yi-Cheng Cheng; Jui-Hung Yen; Ching-Huai Ko; Shu-Jiau Chiou; I-Horng Pan; Hsiang-Wen Tseng
Journal:  BMC Complement Altern Med       Date:  2016-08-08       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.